THC Earnings

THC reported its earnings on 2026-04-30, showcasing a revenue of 5.37B against an estimate of 5.39B, resulting in a -0.41% surprise. The EPS was 4.82, surpassing the expected 4.21 by 14.49%. The stock experienced a -1.65% price change on the earnings day and a 3.78% change over the next five days, reflecting market reactions to the results.

Following THC's earnings announcement on 2026-04-30, the stock price moved by -1.65% on the day of the release. Over the subsequent five days, it saw a 3.78% change. Historically, THC's stock price tends to shift by an average of -3.19% in the 10 days leading up to earnings and 5.02% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate THC's annual revenue to reach 5.50B, while the EPS is projected at 4.08. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between THC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, THC's stock price typically moves by -3.19% in the 10 days before its earnings and 5.02% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 4.08 and revenue of 5.50B.

The earnings call summary shows mixed results. Basic financial performance is stable, but no year-over-year growth in key metrics. Product development is positive with high-acuity service growth. Market strategy is stable, with successful M&A but no groundbreaking changes. Expenses are managed well, but concerns about payer denials and Medicaid trends persist. Shareholder returns are positive with share repurchases. Q&A insights reveal stable but unimproved payer dynamics and some strategic successes, balancing out the lack of strong guidance changes. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.